NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Ascending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
23155-0875-10 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 1, 2023 | In Use | ||
00430-0720-24 | 00430-0720 | Estradiol | ESTRACE | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec. 26, 2011 | Aug. 31, 2025 | In Use | |
00430-0721-24 | 00430-0721 | Estradiol | ESTRACE | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec. 26, 2011 | Aug. 31, 2025 | In Use | |
00430-0722-24 | 00430-0722 | Estradiol | ESTRACE | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec. 26, 2011 | Aug. 31, 2025 | In Use | |
16729-0436-30 | 16729-0436 | Fulvestrant | FULVESTRANT | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Jan. 21, 2021 | In Use | ||
62935-0227-10 | 62935-0227 | Leuprolide acetate | Eligard | 22.5 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov. 27, 2023 | In Use | ||
62935-0306-40 | 62935-0306 | Leuprolide acetate | Eligard | 30.0 mg/.5mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 11, 2024 | In Use | ||
62935-0756-80 | 62935-0756 | Leuprolide acetate | Eligard | 7.5 mg/.25mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov. 1, 2023 | In Use | ||
70860-0210-51 | 70860-0210 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | March 13, 2019 | Sept. 30, 2024 | In Use | |
42291-0374-90 | 42291-0374 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 5, 2015 | In Use | ||
42291-0374-30 | 42291-0374 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 4, 2024 | In Use | ||
51655-0520-52 | 51655-0520 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Dec. 27, 2023 | In Use | ||
55150-0336-01 | 55150-0336 | TESTOSTERONE ENANTHATE | TESTOSTERONE ENANTHATE | 200.0 mg/mL | Hormonal Therapy | Androgen | Intramuscular | Feb. 28, 2024 | In Use | ||
72162-2208-06 | 72162-2208 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 5, 2024 | In Use | ||
72162-2209-03 | 72162-2209 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 5, 2024 | In Use | ||
82868-0026-30 | 82868-0026 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 9, 2023 | In Use | ||
82868-0038-30 | 82868-0038 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 5, 2024 | In Use | ||
82868-0038-90 | 82868-0038 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan. 18, 2024 | In Use | ||
83634-0203-74 | 83634-0203 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Feb. 28, 2024 | In Use | ||
57377-0025-01 | 57377-0025 | Estradiol pellet | Estra-25 | 25.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
57377-0050-01 | 57377-0050 | Estradiol pellet | Estra-50 | 50.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
68001-0610-25 | 68001-0610 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Feb. 28, 2024 | In Use | ||
68788-8626-01 | 68788-8626 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | April 9, 2024 | In Use | ||
68788-8626-03 | 68788-8626 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | April 9, 2024 | In Use | ||
68788-8626-06 | 68788-8626 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | April 9, 2024 | In Use |
Found 10,000 results in 3 milliseconds — Export these results